ClinicalTrials.gg
CompletedNCT02549001Updated Sep 26, 2018

Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis

A Phase 3 interventional study of P-3058 10% and vehicle of P-3058 10% in Onychomycosis, sponsored by Polichem S.A.. Completed at 13 sites in 13 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-09-26.

Sponsored by Polichem S.A. (part of Almirall, S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
953
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether P-3058 nail solution is a safe and effective treatment for onychomycosis.

02

Conditions studied

  • Onychomycosis

Browse trials for

Keywords

  • Onychomycosis
  • Nail fungus
03

In context

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

This study's enrollment of 953 is above the median of 60 across 143 interventional studies indexed under Onychomycosis.

Browse Onychomycosis studies →

Lead sponsor

Polichem S.A. is the lead sponsor of 7 studies on the registry; none are open to participants now.

First submitted before Polichem S.A. became part of Almirall, S.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Patients aged 12 years and older of any race.
  • Males or females.
  • Patients with onychomycosis involving ≥ 20% to ≤ 50% of target big toenail.
  • Patients with a positive KOH examination and culture positive for dermatophyte

Exclusion criteria

Exclusion Criteria:

  • Presence of "yellow spikes" on the target nail.
  • Presence of dermatophytoma on the target nail.
  • Presence of nail thickness exceeding 2 mm.
  • Patients with proximal subungual involvement
  • Patients with severe plantar or moccasin tinea pedis
  • Patients with nail abnormalities due to other conditions
  • Patients with less than 2 years.
  • Chemotherapy, therapy in the 12 weeks prior to Screening visit (V1).
  • Systemic , antimetabolites and immune-stimulants therapy in the 4 weeks prior to Screening visit (V1).
  • infection or any other immunodeficiency.
  • Alcohol or substance abuse.
  • Patients with history of allergic reactions to terbinafine or its .
  • Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
953 participants (actual)

Study arms

  • Experimental
    P-3058 10%

    P-3058 10%

    Drug: P-3058 10%

  • Placebo comparator
    vehicle of P-3058 10%

    vehicle of P-3058 10%

    Drug: vehicle of P-3058 10%

  • Active comparator
    amorolfine 5%

    Loceryl®

    Drug: amorolfine 5%

Interventions

  • DrugP-3058 10%
  • Drugvehicle of P-3058 10%
  • Also known as: Loceryl®

06

What researchers measure

Primary outcomes

  1. Complete cure of target great toenail defined as negative KOH microscopy, negative culture for dermatophytes and target nail totally clear.

    Time frame: Week 60

Secondary outcomes

  1. Responder rate of the target toenail, defined as negative KOH microscopy, negative culture for dermatophytes and ≤10% residual involvement of the target toenail.

    Time frame: Week 60

  2. Negative culture rate for dermatophytes of the target nail.

    Time frame: Week 60

  3. Mycological cure defined as negative KOH microscopy and negative culture for dermatophytes of the target nail.

    Time frame: Week 60

  4. Overall safety by recording any AE during the entire study duration and the local tolerability by means of severity scores for skin irritation.

    Time frame: Week 60

07

Study locations

13 sites
  • Polichem Investigative Site
    Multiple Locations, Belgium
  • Polichem Investigative Site
    Multiple Locations, Bulgaria
  • Polichem Investigative Site
    Multiple Locations, Czechia
  • Polichem Investigative Site
    Multiple Locations, Germany
  • Polichem Investigative Site
    Multiple Locations, Greece
  • Polichem Investigative Site
    Multiple Locations, Hungary
  • Polichem Investigative Site
    Various Cities In Iceland, Iceland
  • Polichem Investigative Site
    Multiple Locations, Latvia
  • Polichem Investigative Site
    Multiple Locations, Lithuania
  • Polichem Investigative Site
    Multiple Locations, Poland
  • Polichem Investigative Site
    Multiple Locations, Russian Federation
  • Polichem Investigative Site
    Multiple Locations, Slovakia
  • Polichem Investigative Site
    Multiple Locations, Sweden
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Sep 2018, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2015
First posted
Sep 14, 2015
StartActual
Aug 20, 2015
Primary completionActual
Sep 17, 2018
CompletionActual
Sep 17, 2018
Last update
Sep 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02549001
Lead sponsor
Polichem S.A.
Responsible party
Sponsor
First posted
Sep 14, 2015
Start date
Aug 20, 2015
Primary completion
Sep 17, 2018
Completion
Sep 17, 2018
Last update
Sep 26, 2018

Study contacts

Maurizio Caserini, MD
study director · Polichem S.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion